144 related articles for article (PubMed ID: 20176012)
1. The novel, peripherally restricted GABAB receptor agonist lesogaberan (AZD3355) inhibits acid reflux and reduces esophageal acid exposure as measured with 24-h pHmetry in dogs.
Brändén L; Fredriksson A; Harring E; Jensen J; Lehmann A
Eur J Pharmacol; 2010 May; 634(1-3):138-41. PubMed ID: 20176012
[TBL] [Abstract][Full Text] [Related]
2. (R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action.
Lehmann A; Antonsson M; Holmberg AA; Blackshaw LA; Brändén L; Bräuner-Osborne H; Christiansen B; Dent J; Elebring T; Jacobson BM; Jensen J; Mattsson JP; Nilsson K; Oja SS; Page AJ; Saransaari P; von Unge S
J Pharmacol Exp Ther; 2009 Nov; 331(2):504-12. PubMed ID: 19648470
[TBL] [Abstract][Full Text] [Related]
3. Lesogaberan, a GABA(B) agonist for the potential treatment of gastroesophageal reflux disease.
Bredenoord AJ
IDrugs; 2009 Sep; 12(9):576-84. PubMed ID: 19697277
[TBL] [Abstract][Full Text] [Related]
4. GABAB receptor agonism as a novel therapeutic modality in the treatment of gastroesophageal reflux disease.
Lehmann A; Jensen JM; Boeckxstaens GE
Adv Pharmacol; 2010; 58():287-313. PubMed ID: 20655487
[TBL] [Abstract][Full Text] [Related]
5. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease.
Boeckxstaens GE; Beaumont H; Mertens V; Denison H; Ruth M; Adler J; Silberg DG; Sifrim D
Gastroenterology; 2010 Aug; 139(2):409-17. PubMed ID: 20451523
[TBL] [Abstract][Full Text] [Related]
6. Translational gastrointestinal pharmacology in the 21st century: 'the lesogaberan story'.
Boeckxstaens GE; Denison H; Jensen JM; Lehmann A; Ruth M
Curr Opin Pharmacol; 2011 Dec; 11(6):630-3. PubMed ID: 22036168
[TBL] [Abstract][Full Text] [Related]
7. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial.
Boeckxstaens GE; Beaumont H; Hatlebakk JG; Silberg DG; Björck K; Karlsson M; Denison H
Gut; 2011 Sep; 60(9):1182-8. PubMed ID: 21402616
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of transient lower esophageal sphincter relaxation in GERD: will lesogaberan advance the field?
Falk GW
Gastroenterology; 2010 Aug; 139(2):377-9. PubMed ID: 20600061
[No Abstract] [Full Text] [Related]
9. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy?
Beaumont H; Boeckxstaens GE
Am J Gastroenterol; 2009 Jul; 104(7):1764-71. PubMed ID: 19491837
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial.
Shaheen NJ; Denison H; Björck K; Karlsson M; Silberg DG
Gut; 2013 Sep; 62(9):1248-55. PubMed ID: 22730470
[TBL] [Abstract][Full Text] [Related]
11. Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects.
Boeckxstaens GE; Rydholm H; Lei A; Adler J; Ruth M
Aliment Pharmacol Ther; 2010 Jun; 31(11):1208-17. PubMed ID: 20222915
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.
Alstermark C; Amin K; Dinn SR; Elebring T; Fjellström O; Fitzpatrick K; Geiss WB; Gottfries J; Guzzo PR; Harding JP; Holmén A; Kothare M; Lehmann A; Mattsson JP; Nilsson K; Sundén G; Swanson M; von Unge S; Woo AM; Wyle MJ; Zheng X
J Med Chem; 2008 Jul; 51(14):4315-20. PubMed ID: 18578471
[TBL] [Abstract][Full Text] [Related]
13. The GABA(B) receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study.
Beaumont H; Smout A; Aanen M; Rydholm H; Lei A; Lehmann A; Ruth M; Boeckxstaens G
Aliment Pharmacol Ther; 2009 Nov; 30(9):937-46. PubMed ID: 19650825
[TBL] [Abstract][Full Text] [Related]
14. Novel treatments of GERD: focus on the lower esophageal sphincter.
Lehmann A
Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():103-10. PubMed ID: 18924449
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists.
Blackshaw LA; Staunton E; Lehmann A; Dent J
Am J Physiol; 1999 Oct; 277(4):G867-74. PubMed ID: 10516154
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study.
Miner PB; Silberg DG; Ruth M; Miller F; Pandolfino J
BMC Gastroenterol; 2014 Nov; 14():188. PubMed ID: 25407279
[TBL] [Abstract][Full Text] [Related]
17. GABAB receptors as drug targets to treat gastroesophageal reflux disease.
Lehmann A
Pharmacol Ther; 2009 Jun; 122(3):239-45. PubMed ID: 19303900
[TBL] [Abstract][Full Text] [Related]
18. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects.
Lidums I; Lehmann A; Checklin H; Dent J; Holloway RH
Gastroenterology; 2000 Jan; 118(1):7-13. PubMed ID: 10611148
[TBL] [Abstract][Full Text] [Related]
19. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial.
Omari TI; Benninga MA; Sansom L; Butler RN; Dent J; Davidson GP
J Pediatr; 2006 Oct; 149(4):468-74. PubMed ID: 17011315
[TBL] [Abstract][Full Text] [Related]
20. Effect of sodium valproate on esophageal motility in healthy subjects and patients with gastroesophageal reflux.
Tzovaras G; Tsiaoussis J; Athanasakis E; Zoras O; Xynos E; Chrysos E
Scand J Gastroenterol; 2004 Jun; 39(6):521-6. PubMed ID: 15223674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
